My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 292

    1.

    Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.

    Smith DH, Fenn P, Drummond M.

    Br J Ophthalmol. 2004 Sep;88(9):1107-12.PMID: 15317697 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

    Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.

    Ophthalmology. 2001 Nov;108(11):2051-9.PMID: 11713079 [PubMed - indexed for MEDLINE]Related articles

    3.

    Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

    Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

    Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles

    4.

    The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

    Brown GC, Brown MM, Campanella J, Beauchamp GR.

    Am J Ophthalmol. 2005 Oct;140(4):679-87.PMID: 16226519 [PubMed - indexed for MEDLINE]Related articles

    5.

    Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

    Clin Ther. 2008 Dec;30(12):2436-51.PMID: 19167602 [PubMed - indexed for MEDLINE]Related articles

    6.

    Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

    Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.PMID: 18462575 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

    Earnshaw SR, Moride Y, Rochon S.

    Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.PMID: 18035208 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

    Hopley C, Salkeld G, Mitchell P.

    Br J Ophthalmol. 2004 Aug;88(8):982-7.PMID: 15258009 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    [Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland]

    Donati G.

    J Fr Ophtalmol. 2007 Oct;30(8):837-41. French. PMID: 17978682 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

    Shepherd J, Jones J, Takeda A, Davidson P, Price A.

    Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

    Ophthalmology. 2007 Jun;114(6):1170-8. Epub 2007 Feb 23.PMID: 17320964 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy.

    Greiner RA.

    Semin Ophthalmol. 2001 Dec;16(4):218-22.PMID: 15513444 [PubMed - indexed for MEDLINE]Related articles

    13.

    The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

    Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

    Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.PMID: 17999842 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.

    Bansback N, Davis S, Brazier J.

    Eye (Lond). 2007 Dec;21(12):1455-63. Epub 2006 Nov 10.PMID: 17086167 [PubMed - indexed for MEDLINE]Related articles

    15.

    Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.

    Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H.

    Curr Med Res Opin. 2005 Jul;21(7):1005-14.PMID: 16004667 [PubMed - indexed for MEDLINE]Related articles

    16.

    A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

    Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

    Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.PMID: 16904046 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The cost-effectiveness of testing for hepatitis C in former injecting drug users.

    Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

    Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.PMID: 16948891 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

    Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.PMID: 17999840 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

    Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

    Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.PMID: 16409879 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

    Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.

    Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.PMID: 16796930 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity